Does ex vivo CD34+ positive selection influence outcome after autologous hematopoietic stem cell transplantation in systemic sclerosis patients?

Bone Marrow Transplantation

Volumn 51, Issue 4, 2016, Pages 501-505

  Oliveira, M C ^a   Labopin, M ^b   Henes, J ^c   Moore, J ^d   Papa, N D ^e   Cras, A ^f,g   Sakellari, I ^h   Schroers, R ⁱ   Scherer, H U ^j   Cuneo, A ^k   Kyrcz Krzemien, S ^l   Daikeler, T ^m   Alexander, T ⁿ   Finke, J ^o   Badoglio, M ^b   Simoes B ^a   Snowden, J A ^p   Farge, D ^f,q  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b HÔPITAL SAINT ANTOINE   (France)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d ST VINCENT S HOSPITAL   (Australia)

^e ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

^f SAINT LOUIS HOSPITAL   (France)

^g Fondation Carpentier   (France)

^h G PAPANICOLAOU HOSPITAL   (Greece)

ⁱ RUHR UNIVERSITY BOCHUM   (Germany)

^j LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^k UNIVERSITY OF FERRARA   (Italy)

^l MEDICAL UNIVERSITY OF SILESIA   (Poland)

^m UNIVERSITY HOSPITAL BASEL   (Switzerland)

ⁿ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^o UNIVERSITY OF FREIBURG   (Germany)

^p SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^q UNIVERSITÉ PARIS DESCARTES   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CD34 SELECTION; CHILD; CONTROLLED STUDY; DISEASE COURSE; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RELAPSE; RETROSPECTIVE STUDY; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME; AUTOGRAFT; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; MULTICENTER STUDY; PROCEDURES; SCLERODERMA, SYSTEMIC; SURVIVAL RATE;

CD34 ANTIGEN;

ADOLESCENT; ADULT; ANTIGENS, CD34; AUTOGRAFTS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; SCLERODERMA, SYSTEMIC; SURVIVAL RATE;

EID: 84949292966     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2015.299     Document Type: Article

References (28)

1. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009; 360: 1989-2003
2. Domsic RT, Medsger TA Jr. Connective tissue diseases: predicting death in SSc: planning and cooperation are needed. Nat Rev Rheumatol 2011; 7: 628-630
3. Fransen J, Popa-Diaconu D, Hesselstrand R, Carreira P, Valentini G, Beretta L et al. Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres. Ann Rheum Dis 2011; 70: 1788-1792
4. Binks M, Passweg JR, Furst D, McSweeney P, Sullivan K, Besenthal C et al. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann Rheum Dis 2001; 60: 577-584
5. Farge D, Marolleau JP, Zohar S, Marjanovic Z, Cabane J, Mounier N et al. Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I-II study. Br J Haematol 2002; 119: 726-739
6. Nash RA, McSweeney PA, Crofford LJ, Abidi M, Chen CS, Godwin JD et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood 2007; 110: 1388-1396
7. Oyama Y, Barr WG, Statkute L, Corbridge T, Gonda EA, Jovanovic B et al. Autologous non-myeloablative hematopoietic stem cell transplantation in patients with systemic sclerosis. Bone Marrow Transplant 2007; 40: 549-555
8. Farge D, Passweg J, van Laar JM, Marjanovic Z, Besenthal C, Finke J et al. Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. Ann Rheum Dis 2004; 63: 974-981
9. Burt RK, Shah SJ, Dill K, Grant T, Gheorghiade M, Schroeder J et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 2011; 378: 498-506
10. Van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 2014; 311: 2490-2498
11. Farge D, Labopin M, Tyndall A, Fassas A, Mancardi GL, Van Laar J et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune diseases. Haematologica 2010; 95: 284-292
12. Snowden JA, Saccardi R, Allez M, Ardizzone S, Arnold R, Cervera R et al. Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2012; 47: 770-790
13. Burt RK, Oliveira MC, Shah SJ, Moraes DA, Simoes B, Gheorghiade M et al. Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: a retrospective analysis. Lancet 2013; 381: 1116-1124
14. Saccardi R, Tyndall A, Coghlan G, Denton C, Edan G, Emdin M et al. Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference tosystemic sclerosis and multiplesclerosis. Bone Marrow Transplant 2004; 34: 877-881
15. Burt RK, Shah SJ, Gheorghiade M, Ruderman E, Schroeder J. Hematopoietic stem cell transplantation for systemic sclerosis: if you are confused, remember: 'it is a matter of the heart'. J Rheumatol 2012; 39: 206-209
16. Martínez C, Urbano-Ispizua A, Rozman C, Marín P, Rovira M, Sierra J et al. Immune reconstitution following allogeneic peripheral blood progenitor cell transplantation: comparison of recipients of positive CD34+ selected grafts with recipients of unmanipulated grafts. Exp Hematol 1999; 27: 561-568
17. Marek A, Stern M, Chalandon Y, Ansari M, Ozsahin H, Güngör T et al. The impact of T-cell depletion techniques on the outcome after haploidentical hematopoietic SCT. Bone Marrow Transplant 2014; 49: 55-61
18. Kohno K, Nagafuji K, Tsukamoto H, Horiuchi T, Takase K, Aoki K et al. Infectious complications in patients receiving autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. Transpl Infect Dis 2009; 11: 318-323
19. Alchi B, Jayne D, Labopin M, Demin A, Sergeevicheva V, Alexander T et al. Autologous haematopoietic stem cell transplantation for systemic lupus erythematosus: data from the European Group for Blood and Marrow Transplantation registry. Lupus 2013; 22: 245-253
20. Moore J, Brooks P, Milliken S, Biggs J, Ma D, Handel M et al. A pilot randomized trial comparing CD34-selected versus unmanipulated hemopoietic stem cell transplantation for severe, refractory rheumatoid arthritis. Arthritis Rheum 2002; 46: 2301-2309
21. Saccardi R, Kozak T, Bocelli-Tyndall C, Fassas A, Kazis A, Havrdova E et al. Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. Mult Scler 2006; 12: 814-823
22. Fassas A, Anagnostopoulos A, Kazis A, Kapinas K, Sakellari I, Kimiskidis V et al. Autologous stem cell transplantation in progressive multiple sclerosis-an interim analysis of efficacy. J Clin Immunol 2000; 20: 24-30
23. Carreras E, Saiz A, Marín P, Martínez C, Rovira M, Villamor N et al. CD34+ selected autologous peripheral blood stem cell transplantation for multiple sclerosis: report of toxicity and treatment results at one year of follow-up in 15 patients. Haematologica 2003; 88: 306-314
24. Nash RA, Dansey R, Storek J, Georges GE, Bowen JD, Holmberg LA et al. Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. Biol Blood Marrow Transplant 2003; 9: 583-591
25. Zhang L, Bertucci AM, Ramsey-Goldman R, Burt RK, Datta SK. Regulatory T cell (Treg) subsets return in patients with refractory lupus following stem cell transplantation and TGF-beta-producing CD8. Treg cells are associated with immunological remission of lupus. J Immunol 2009; 183: 6346-6358
26. Marmont Champ AM. Hematopoietic stem cell transplantation for systemic lupus erythematosus. Clin Dev Immunol 2012; 2012: 380391
27. Alexander T, Bondanza A, Muraro PA, Greco R, Saccardi R, Daikeler T et al. SCT for severe autoimmune diseases: consensus guidelines of the European Society for Blood and Marrow Transplantation for immune monitoring and biobanking. Bone Marrow Transplant 2015; 50: 173-180
28. Muraro PA, Robins H, Malhotra S, Howell M, Phippard D, Desmarais C et al. T cell repertoire following autologous stem cell transplantation for multiple sclerosis. J Clin Invest 2014; 124: 1168-1172